Every 8-K that Mannkind Corporation (MNKD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MNKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNKD filings page.
MannKind Corporation (MNKD) reported that on August 21, 2026 it filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-285286) with the SEC. On the same date, MannKind furnished an opinion of Cooley LLP regarding the legality of the issuance and sale of the common stock described in that prospectus supplement, included as Exhibit 5.1, together with Cooley LLP’s related consent as Exhibit 23.1.
MannKind Corporation reported Q2 2026 total revenues of $109,374 (thousands), a 43% increase from Q2 2025, driven by the addition of Furoscix, higher collaborations and services revenue, and royalties tied to Tyvaso DPI. Commercial product sales were $41,982 (thousands), including Furoscix net sales of $22,191 (thousands) and Afrezza net sales of $17,021 (thousands). For the first six months of 2026, total revenues reached $199,544 (thousands), up 29% year over year.
Higher cost of goods, research and development, and selling, general and administrative expenses, largely associated with Furoscix and pipeline advancement, led to a Q2 2026 net loss of $19,032 (thousands), or $0.06 per basic share, compared with net income of $668 (thousands) a year earlier. Non-GAAP adjusted net loss was $2,660 (thousands) versus non-GAAP income of $13,901 (thousands). Cash, cash equivalents and investments totaled $111 million as of June 30, 2026, and a $50 million private placement closed on July 24, 2026 to fund a $45 million contingent value right payment following FDA approval of the Furoscix ReadyFlow autoinjector. During 2026, MannKind also received FDA approval for a pediatric indication for Afrezza and reported positive Phase 1b data for its nintedanib DPI program while preparing an IND for ralinepag DPI.
MannKind Corporation completed a $50.0 million private placement with institutional accredited investors, selling 10,440,838 shares of common stock at $3.89 per share and pre-funded warrants for 2,412,632 underlying shares at $3.88 per warrant share. The pre-funded warrants have a $0.01 exercise price, are exercisable on a cashless basis, do not expire until fully exercised, and include a beneficial ownership limitation not to exceed 19.99%.
The company plans to use net proceeds for general corporate purposes, including funding a $45.0 million contingent value rights payment obligation triggered by the U.S. Food and Drug Administration’s approval of Furoscix ReadyFlow (furosemide injection). The securities were issued under the Section 4(a)(2) exemption, with resale registration rights for the shares and warrant shares to be filed within 30 days of closing. Separately, the FDA approved Furoscix ReadyFlow to treat edema in adults with heart failure or chronic kidney disease.
MannKind Corporation reported that the U.S. Food and Drug Administration approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes. This expands Afrezza’s use beyond adults into the pediatric diabetes population.
The FDA also stated that the supplemental biologics license application for this pediatric indication has fulfilled the last remaining postmarketing requirement for Afrezza from its original June 27, 2014 approval. This means all originally required follow-up obligations for Afrezza have now been completed.
MannKind Corporation reports a key regulatory change and a pediatric clinical update for its inhaled insulin Afrezza. The FDA has released the company from a postmarketing requirement to run a five-year, randomized trial in 8,000-10,000 adults with type 2 diabetes to assess pulmonary malignancy risk versus standard care. The only remaining postmarketing requirement for Afrezza is a study of efficacy and safety in pediatric patients.
The FDA is reviewing a supplemental Biologics License Application for Afrezza use in children and adolescents aged 4-17 with a PDUFA target action date of May 29, 2026. MannKind is also enrolling the INHALE-1st study in youth aged 10-17 with newly diagnosed type 1 diabetes, following up to 100 participants across 10 sites for 13 weeks, with an optional 26-week extension, and expects data in late 2027.
MannKind Corporation reported results from its 2026 Annual Meeting of Stockholders held on May 20, 2026. Stockholders elected nine directors, each receiving over 140 million shares voted in favor, with sizable broker non-votes recorded on the election items.
Stockholders approved, on an advisory basis, the compensation of MannKind’s named executive officers, with 137,332,418 shares voted for, 16,295,138 against, 1,303,497 abstaining, and 78,531,407 broker non-votes. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for 2026, with 221,079,329 shares for, 8,759,982 against, and 3,623,149 abstaining.
MannKind Corporation reported first quarter 2026 total revenues of 90,171 (in thousands), up 15% from 78,354 (in thousands) a year earlier, driven mainly by Furoscix and higher royalties from Tyvaso DPI. Furoscix net sales were 15,493 (in thousands), while Afrezza net sales were 15,273 (in thousands).
Despite revenue growth, MannKind recorded a net loss of 16,619 (in thousands) versus net income of 13,158 (in thousands) in 2025 as cost of goods sold, research and development, and selling, general and administrative expenses all rose sharply, including amortization of acquired intangibles. The company highlighted upcoming PDUFA dates for Afrezza pediatrics and the Furoscix ReadyFlow Autoinjector, progress of MNKD-201 into Phase 2, an expanded ralinepag DPI collaboration with a 5,000 (in thousands) payment and up to 35,000 (in thousands) in potential milestones, and cash, cash equivalents and investments totaling 134 million as of March 31, 2026.
MannKind Corporation reported strong top-line growth for the fourth quarter and full year 2025, driven by its cardiometabolic and inhaled therapies portfolio. Q4 2025 revenues were $111.9 million, up 46% from Q4 2024, with full year 2025 revenues of $349.0 million, a 22% increase over 2024.
Growth came from higher royalties on Tyvaso DPI, increased collaborations and services for United Therapeutics, and rising Afrezza sales, plus $23.2 million of Furoscix revenue added after acquiring scPharmaceuticals in October 2025. Despite this, MannKind recorded a Q4 2025 net loss of $15.9 million and full year 2025 net income of $5.9 million, down from $27.6 million in 2024, as R&D and SG&A spending rose sharply to support pipeline development and the Furoscix launch.
MannKind Corporation filed Amendment No. 1 to a prior current report related to its completed merger with scPharmaceuticals Inc. The update focuses on providing fuller financial information for the acquired business and the combined company.
The amendment adds audited consolidated financial statements of scPharma for the year ended December 31, 2024, unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2025, and unaudited pro forma condensed combined financial information for MannKind for the six months ended June 30, 2025 and the year ended December 31, 2024. It also lists related exhibits, including the merger agreement, a contingent value rights agreement, a loan agreement amendment, and the auditor’s consent, while leaving all other parts of the original report unchanged.
MannKind Corporation is discontinuing its Phase 3 trial of nebulized clofazimine (MNKD-101) for refractory nontuberculous mycobacterial lung disease after an interim analysis for the first 46 participants who completed the double-blind phase showed no sputum culture conversions, indicating futility.
The data safety monitoring board reviewed the results on November 8, 2025 and agreed with stopping the study; no safety issues were identified. MannKind plans to investigate the outcome and apply learnings to MNKD-102, a dry powder clofazimine formulation progressing from pre-clinical toward Phase 1.
MannKind Corporation furnished a current report to announce that it issued a press release addressing results of operations and financial condition. The press release is included as Exhibit 99.1. This administrative update signals that the company has released its latest performance communication, with full details contained in the accompanying press release.
MannKind Corporation entered into a merger agreement to acquire scPharmaceuticals, Inc. via a tender offer that began on September 8, 2025. The offer paid $5.35 in cash per scPharma share plus one non‑tradable contingent value right (CVR) per share that can pay up to $1.00 total if regulatory and sales milestones are met.
The CVRs pay up to $0.75 for FDA approval of an injection product by September 30, 2026 (reduced amounts for later approval) and up to additional payments tied to trailing 12‑month worldwide net sales of at least $110.0M (with full payment at $120.0M). Approximately 73.47% of scPharma shares were validly tendered by the offer's expiration, with guaranteed delivery notices for ~10.91% more; the merger closed by completing a short-form merger on October 7, 2025.
The acquisition was funded from available cash and borrowings under an amended credit facility that included an incremental delayed draw term loan commitment of $175.0M, and MannKind also funded debt extinguishment of approximately $82.6M. The amended credit terms include a pricing grid tied to a leverage test and an interest margin step‑up to 5.00% if net leverage reaches 5.00:1.00.
MannKind Corporation has expanded its long‑running collaboration with United Therapeutics through a first amendment to their 2018 global license and collaboration agreement. The amendment documents United Therapeutics’ decision to add an additional development product to the scope of the partnership.
MannKind will formulate an investigational molecule for this additional product using its Technosphere® platform and will supply specified quantities of clinical trial material, while United Therapeutics will handle all remaining preclinical and clinical development work. In return, MannKind will receive an upfront payment of $5 million, is eligible for up to $35 million in development milestone payments tied to the additional product, and would earn 10% royalties on its net sales if the product is ultimately approved.
MannKind Corporation, through a wholly owned merger subsidiary, will commence a tender offer to acquire all outstanding shares of scPharmaceuticals for $5.35 cash per share plus one non-tradeable contingent value right (CVR) that can pay up to an additional $1.00 per CVR based on two milestone tests. If the Offer is successful and conditions are met, Purchaser will merge into scPharmaceuticals, leaving scPharmaceuticals as a direct wholly owned subsidiary of MannKind.
The CVR pays up to $0.75, $0.50, or $0.25 per CVR for FDA approval timing of an injection product tied to SCP-111, and additional sales-based payments of up to $0.25 per CVR tied to $110.0–$120.0 million of trailing 12-month worldwide net sales. Principal stockholders holding approximately 11.5% of scPharmaceuticals have agreed to tender and support the transaction. Lenders led by Blackstone agreed to an amendment providing an additional $175.0 million incremental delayed-draw term loan to finance transaction costs, and Parent must repay and buy out Target’s Perceptive obligations estimated at $81.0 million on closing.